Ikuta K, Suzuki S, Horikoshi H, Mukai T, Luftig R B
Department of Virology, Research Institute for Microbial Diseases (Biken), Osaka University, Suita, Osaka 565-0871, Japan.
Microbiol Mol Biol Rev. 2000 Dec;64(4):725-45. doi: 10.1128/MMBR.64.4.725-745.2000.
In this review we summarize multiple aspects of the human immunodeficiency virus (HIV) protease from both structural and functional viewpoints. After an introductory overview, we provide an up-to-date status report on protease inhibitors (PI). This proceeds from a discussion of PI structural design, to how PI are optimally utilized in highly active antiretroviral triple therapy (one PI along with two reverse transcriptase inhibitors), the emergence of PI resistance, and the natural role of secretory leukocyte PI. Then we switch to another focus: the interaction of HIV protease with other genes in acute and persistent infection, which in turn may have an effect on AIDS pathogenesis. We conclude with a discussion on future directions in HIV treatment, involving multiple-target anti-HIV therapy, vaccine development, and novel reactivation-inhibitory reagents.
在本综述中,我们从结构和功能的角度总结了人类免疫缺陷病毒(HIV)蛋白酶的多个方面。在进行介绍性概述之后,我们提供了关于蛋白酶抑制剂(PI)的最新现状报告。这部分内容从PI的结构设计讨论开始,接着阐述PI在高效抗逆转录病毒三联疗法(一种PI与两种逆转录酶抑制剂联用)中的最佳使用方式、PI耐药性的出现,以及分泌型白细胞PI的天然作用。然后我们转向另一个重点:HIV蛋白酶在急性和持续性感染中与其他基因的相互作用,这反过来可能对艾滋病发病机制产生影响。我们最后讨论了HIV治疗的未来方向,包括多靶点抗HIV疗法、疫苗开发和新型再激活抑制试剂。